These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32933548)

  • 1. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model.
    Kim JM; Kim DH; Park HJ; Ma HW; Park IS; Son M; Ro SY; Hong S; Han HK; Lim SJ; Kim SW; Cheon JH
    J Nanobiotechnology; 2020 Sep; 18(1):133. PubMed ID: 32933548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab does not increase colonic cancer risk associated to murine chronic colitis.
    Lopetuso LR; Petito V; Zinicola T; Graziani C; Gerardi V; Arena V; Caristo ME; Poscia A; Cammarota G; Papa A; Cufino V; Sgambato A; Gasbarrini A; Scaldaferri F
    World J Gastroenterol; 2016 Nov; 22(44):9727-9733. PubMed ID: 27956796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of Lactobacillus gasseri KBL697 and tumor necrosis factor-alpha inhibitor infliximab improves colitis in mice.
    Han DH; Kim WK; Lee C; Park S; Lee K; Jang SJ; Ko G
    Sci Rep; 2022 Jun; 12(1):9640. PubMed ID: 35688918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease.
    Li X; Yu M; Zhu Z; Lu C; Jin M; Rao Y; Zhao Q; Lu X; Yu C
    Carbohydr Polym; 2021 Dec; 273():118556. PubMed ID: 34560967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis.
    de Paula-Silva M; Barrios BE; Macció-Maretto L; Sena AA; Farsky SH; Correa SG; Oliani SM
    Biochem Pharmacol; 2016 Sep; 115():104-13. PubMed ID: 27343762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab.
    Blais A; Lan A; Blachier F; Benamouzig R; Jouet P; Couvineau A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease.
    Bhol KC; Tracey DE; Lemos BR; Lyng GD; Erlich EC; Keane DM; Quesenberry MS; Holdorf AD; Schlehuber LD; Clark SA; Fox BS
    Inflamm Bowel Dis; 2013 Oct; 19(11):2273-81. PubMed ID: 23949620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral colon-targeted responsive alginate/hyaluronic acid-based hydrogel propels the application of infliximab in colitis.
    Huai M; Pei M; Pan J; Zhu Y; Chen Y; Du P; Duan Y; Xu H; Ge W
    Int J Biol Macromol; 2023 Sep; 249():125952. PubMed ID: 37494992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice.
    Lopetuso LR; Petito V; Cufino V; Arena V; Stigliano E; Gerardi V; Gaetani E; Poscia A; Amato A; Cammarota G; Papa A; Sgambato A; Gasbarrini A; Scaldaferri F
    Dig Liver Dis; 2013 Dec; 45(12):1017-21. PubMed ID: 23911613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
    Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
    Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease.
    Román ID; Cano-Martínez D; Lobo MV; Fernández-Moreno MD; Hernández-Breijo B; Sacristán S; Sanmartín-Salinas P; Monserrat J; Gisbert JP; Guijarro LG
    Biomarkers; 2017 Mar; 22(2):133-144. PubMed ID: 27781498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel polyurethane based particulate formulations of infliximab reduce inflammation in DSS induced murine model of colitis - A preliminary study.
    Pabari RM; Tambuwala MM; Lajczak-McGinley N; Aljabali A; Kirby BP; Keely S; Ramtoola Z
    Int J Pharm; 2021 Jul; 604():120717. PubMed ID: 34015378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peanut shell extract inhibits the development of dextran sulfate sodium (DSS)-induced colitis.
    Lee AS; Lee KM; Lee JA; Choi I
    Int Immunopharmacol; 2019 May; 70():235-240. PubMed ID: 30851703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of mucosal integrity and epithelial transport function by concomitant anti-TNFα treatment in chronic DSS-induced colitis.
    Lenzen H; Qian J; Manns MP; Seidler U; Jörns A
    J Mol Med (Berl); 2018 Aug; 96(8):831-843. PubMed ID: 29967942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Targeted Delivery by Nanoparticles Enhances Efficacy of an Hsp90 Inhibitor by Reducing Systemic Exposure in Murine Models of Colitis and Colitis-Associated Cancer.
    Yang M; Zhang F; Yang C; Wang L; Sung J; Garg P; Zhang M; Merlin D
    J Crohns Colitis; 2020 Jan; 14(1):130-141. PubMed ID: 31168612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
    Colombo G; Clemente N; Zito A; Bracci C; Colombo FS; Sangaletti S; Jachetti E; Ribaldone DG; Caviglia GP; Pastorelli L; De Andrea M; Naviglio S; Lucafò M; Stocco G; Grolla AA; Campolo M; Casili G; Cuzzocrea S; Esposito E; Malavasi F; Genazzani AA; Porta C; Travelli C
    J Mol Med (Berl); 2020 Apr; 98(4):595-612. PubMed ID: 32338310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease.
    Zhang S; Kang L; Hu S; Hu J; Fu Y; Hu Y; Yang X
    Int J Biol Macromol; 2021 Jan; 167():1598-1612. PubMed ID: 33220374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-selective oral delivery of therapeutic antibodies to the inflamed colon
    Lee SH; Song JG; Han HK
    Acta Pharm Sin B; 2022 Nov; 12(11):4249-4261. PubMed ID: 36386471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.
    Crowe JS; Roberts KJ; Carlton TM; Maggiore L; Cubitt MF; Clare S; Harcourt K; Reckless J; MacDonald TT; Ray KP; Vossenkämper A; West MR
    Sci Rep; 2018 Mar; 8(1):4941. PubMed ID: 29563546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
    Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
    Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.